

Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice

Thibaud Sefiane,^{1*} Geneviève McCluskey,^{1*} Marie Clavel,² Hortense Maynadié,^{1,3} Ivan Peyron,¹ Tovo David,⁴ Camille Brochier,⁵ François Saller,¹ Mariem Khamari,¹ Cécile V. Denis,^{1,6} Olivier D. Christophe,¹ Peter J. Lenting,¹ Vincent Muczynski^{1,7#} and Caterina Casari^{1#}

¹Université Paris-Saclay, Institut National de la Santé et de la Recherche Médicale, Hémostase Inflammation Thrombose U1176, 94276, Le Kremlin-Bicêtre, France; ²Inovarion, Paris, France; ³Centre de Référence Hémophilie, Hôpital Bicêtre, AP-HP, Université Paris-Saclay, Le Kremlin-Bicêtre, France; ⁴F. Hoffmann-La Roche Ltd., Basel, Basel-Stadt, Switzerland; ⁵Institut Roche, Boulogne-Billancourt, France; ⁶Centre Hospitalier Régional Universitaire Nancy, Nancy, France and ⁷University College London – Cancer Institute, London, UK

**TS and GM contributed equally as first authors.*

#VM and CC contributed equally as senior authors.

Correspondence: P. J. Lenting
peter.lenting@inserm.fr

Received: November 14, 2024.

Accepted: March 21, 2025.

Early view: April 3, 2025.

<https://doi.org/10.3324/haematol.2024.286982>

©2025 Ferrata Storti Foundation


Published under a CC BY-NC license



A consistent clinical factor VIII-equivalence is unlikely to exist for non-factor therapies in hemophilia mice

Sefiane *et al.*

Supplementary figure S1



Legend Supplementary figure S1: Thrombin peak as function of emicizumab or SIA-marstacimab concentration. FVIII-deficient plasma was spiked with different concentrations of recombinant FVIII, emicizumab or a sequence identical analogue (SIA)-marstacimab. Thrombin generation was measured in a microtiter-plate fluorometer (Fluoroskan Ascent; Thermo Labsystems, Helsinki, Finland), with thrombin generation being initiated by the addition of phospholipids (40 µM) and tissue factor (TF, 1 pM) or activated factor XI (FXIa, 175 nM). Presented are thrombin peak values for emicizumab (red symbols) and SIA-marstacimab (blue symbols). Average thrombin peak values for rFVIII are indicated with horizontal dotted lines. Data represent mean±SD of 3-5 measurements.